1416975-49-9

Basic information

• Product Name: N-[4-(2-tert-butoxy-pyridin-4-yl)benzyl]-2,6-dichloro-benzamide
• Synonyms: N-[4-(2-tert-butoxy-pyridin-4-yl)benzyl]-2,6-dichloro-benzamide
• CAS NO: 1416975-49-9
• Molecular Weight: 429.346
• Mol File: 1416975-49-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-[4-(2-tert-butoxy-pyridin-4-yl)benzyl]-2,6-dichloro-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(2-tert-butoxy-pyridin-4-yl)benzyl]-2,6-dichloro-benzamide(1416975-49-9)
• EPA Substance Registry System: N-[4-(2-tert-butoxy-pyridin-4-yl)benzyl]-2,6-dichloro-benzamide(1416975-49-9)

Safety Data

• Hazardous Substances Data: 1416975-49-9(Hazardous Substances Data)

Upstream product

• 1086381-36-3 4-bromo-2-tert-butoxypyridine 
• 1416975-48-8 4-[(2,6-dichloro-benzoylamino)methyl]phenylboronic acid 
• 4659-45-4 2,6-Dichlorobenzoyl chloride 

Downstream Products

• 1416975-30-8 2,6-dichloro-N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide 
• 1416975-55-7 2,6-dichloro-N-[4-(1-chloromethyl-2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide 
• 1416975-42-2 phosphoric acid mono-(4-{4-[(2,6-dichloro-benzoylamino)-methyl]-phenyl}-2-oxo-2H-pyridin-1-ylmethyl) ester 
• 1416975-56-8 phosphoric acid di-tert-butyl ester 4-[4-[(2,6-dichloro-benzoylamino)-methyl]-phenyl]-2-oxo-2H-pyridin-1-ylmethyl ester 

Relevant articles and documents

COMBINATION THERAPY FOR NICOTINE ADDICTION

Disclosed is a combination therapy for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising administering to said mammal an amount of an ALDH-2 inhibitor, such as a compound of Formula (I), in combination with an amount of the nicotinic acetylcholine receptor agonist, varenicline. The disclosure further relates to methods and pharmaceutical compositions useful with the combination therapy.

COMBINATION THERAPY FOR PREVENTING ADDICTION

Disclosed is a novel combination therapy to reduce or prevent the acquisition of a conditioned response in a mammal comprising administering to the mammal a therapeutically effective amount of an aldehyde dehydrogenase (ALDH-2) inhibitor compound, such as a compound of Formula (I), in combination with a substance that produces the conditioned response, such as a medication containing a dopamine-producing agent such as an opioid, whereby the combination acts to reduce or prevent the acquisition of a conditioned response, and the deleterious side-effect of misuse, dependence, abuse, and/or addiction.